One of the principal tools of personalized medicine is the use of companion diagnostics. In this first article in a two-part series on the opportunities and challenges that confront the rise of companion diagnostics, we use case studies to review the different roles that these products and services could play in the continued growth of the pharmaceutical industry. The article can be found here:
From climate risk to resilience: what insurers must do next
In this article by Marakon’s Ofir Eyal, he discusses the crucial role insurers can take by financing and insuring green technologies and supporting the energy...